Canadian-based biopharmaceutical company Immunovaccine has started dosing patients in a Phase Ib/II trial of its vaccine DPX-E7 for the treatment of incurable human papillomavirus (HPV) related oropharyngeal, cervical and anal cancers. (Source: Drug Development Technology)



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image